Ultima-AOD9604 5mg

MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE Anti-Obesity Drug-9604 ,

Products are being shipped without branding for security purposes.

AOD 9604 is a modified variant of Growth Hormone, consisting of a 191 amino acid peptide. The final 15 amino acids (positions 176-191) from the Growth Hormone structure have been synthesized into a specific peptide known as GH Frag 176-191, or AOD 9604.

AOD 9604 is regarded as one of the most effective peptides for weight loss, offering additional advantages that promote fat loss and enhance metabolism, among other benefits.

Pituitary Gland

AOD-9604, also recognized as Tyr-hGH Frag 176-191, has been shown to possess significant fat-burning ability without increasing appetite. It does not affect blood sugar or tissue growth (Heffernan 2001, Ng 2000). AOD-9604 activates fat breakdown (oxidation) through a mechanism that does not involve hGH receptors. It operates independently of hGH, with laboratory research on rodents, pigs, dogs, and humans revealing that AOD-9604 facilitates the release of fat from obese cells while reducing new fat accumulation and enhancing fat oxidation. Notably, AOD-9604 is particularly effective at diminishing abdominal fat.

The next most powerful fat loss peptide is CJC-1295, which increases the overall levels of GH in the body—counteracting the typical decline seen with aging. This is partially why individuals tend to gain fat as they age. If your primary goal is fat loss, it is advisable to refrain from using GHRP products (such as GHRP-6 or GHRP-2) since they may induce increased hunger and elevated cortisol levels. AOD-9604 does not lead to increased appetite or cortisol spikes.

Originally developed in the 1990s by Professor Frank Ng at Monash University in Australia, AOD-9604 (Advanced Obesity Drug) aimed to create an anti-obesity drug that offers the fat-burning benefits of human growth hormone (HGH) without promoting muscle growth.

Recent research has further revealed that besides its fat loss capabilities, AOD 9604 possesses various other regenerative qualities linked to growth hormone. Current clinical trials are exploring its potential applications in osteoarthritis, hypercholesterolemia, and repair of bone and cartilage.

Results from oral glucose tolerance tests have shown that, unlike HGH, AOD 9604 does not adversely affect carbohydrate metabolism. No anti-AOD 9604 antibodies were found in the patients included in the antibody assays, and no withdrawal symptoms or serious adverse effects were reported in connection with AOD 9604 intake in any studies.

AOD 9604 has demonstrated a strong safety and tolerability profile, similar to that of a placebo. It does not produce the negative side effects associated with full-length hGH treatments. AOD 9604 has an excellent safety record and has recently obtained Human GRAS status in the USA.